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Muscular dystrophies are a group of genetic and heterogeneous neuromuscular disorders
characterized by the primary wasting of skeletal muscle. In Duchenne muscular dystrophy
(DMD), the most severe form of these diseases, the mutations in the dystrophin gene
lead to muscle weakness and wasting, exhaustion of muscular regenerative capacity, and
chronic local inflammation leading to substitution of myofibers by connective and adipose
tissue. DMD patients suffer from continuous and progressive skeletal muscle damage fol-
lowed by complete paralysis and death, usually by respiratory and/or cardiac failure. No
cure is yet available, but several therapeutic approaches aiming at reversing the ongoing
degeneration have been investigated in preclinical and clinical settings. Autophagy is an
important proteolytic system of the cell and has a crucial role in the removal of proteins,
aggregates, and organelles. Autophagy is constantly active in skeletal muscle and its role
in tissue homeostasis is complex: at high levels, it can be detrimental and contribute to
muscle wasting; at low levels, it can cause weakness and muscle degeneration, due to
the unchecked accumulation of damaged proteins and organelles. The causal relationship
between DMD pathogenesis and dysfunctional autophagy has been recently investigated.
At molecular level, the Akt axis is one of the key dysregulated pathways, although the
molecular events are not completely understood.The aim of this review is to describe and
discuss the clinical relevance of the recent advances dissecting autophagy and its signaling
pathway in DMD.The picture might pave the way for the development of interventions that
are able to boost muscle growth and/or prevent muscle wasting.
Keywords: skeletal muscle, Duchennemuscular dystrophy,muscle wasting, autophagy,Akt–mTOR axis,mdx mice,
therapeutic target
PATHOLOGICAL FEATURES OF DYSTROPHIN DEFICIENCY
Duchenne muscular dystrophy (DMD) is the most frequent and
lethal form of muscular dystrophy, affecting 1 out of 3,500 new-
borns (Govoni et al., 2013). DMD is an X-linked disorder caused by
mutations of the largest gene of the human genome, the dystrophin
gene. So far, more than 4,700 mutations have been identified and
classified as deletions (65.8%), duplications (13.6%), and point
mutations (micro-insertions, microdeletions, and nonsense, mis-
sense, and splicing mutations; 20.6%) (Magri et al., 2011). Muta-
tions that change the reading frame of the gene generally result in
premature stop codons with complete loss of dystrophin in DMD
muscles. Other mutations can result in the generation of a smaller
size-dystrophin or in a lesser amount of the protein being pro-
duced leading to the allelic dystrophinopathy disorder known as
Becker muscular dystrophy, a disease milder than DMD, affecting
1 of 18,518 male births (Emery, 1991).
The diagnosis of DMD and Becker muscular dystrophy is
based on careful analysis of the clinical features and confirmed by
additional investigations including muscle biopsy and/or genetic
testing. In particular, DMD is characterized by an early onset
before 3 years of age, then ambulation loss occurs between 10
and 14 years of age, and finally death takes place between 20 and
30 years of age (Davies et al., 1988).
The most impaired muscle in DMD patients is the diaphragm,
and its wasting is responsible for the respiratory failure (reduced
wall and lung compliance, hypoventilation, hypercapnia, and
hypoxemia) and thus death (Fayssoil et al., 2010; Mosqueira et al.,
2013). DMD also affects cardiac muscle, and to a lesser extent,
smooth muscle (Fayssoil et al., 2010; Mosqueira et al., 2013). More
than 90% of DMD patients are affected by some degree of car-
diomyopathy (Fayssoil et al., 2010; Mosqueira et al., 2013), which
causes a progressive reduction in the ejection fraction, which may
hesitate in heart failure with or without concomitant arrhythmias
(Jefferies et al., 2005). The onset of cardiomyopathy is variable,
starting from 18 years of age in DMD patients (Spurney, 2011;
Politano and Nigro, 2012). Cardiac decline is observed also in
Becker muscular dystrophy patients, which progresses faster than
skeletal muscle decline (Bushby et al., 2010).
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Functionally, dystrophic skeletal muscles are more susceptible
to eccentric contraction than the healthy ones (Lynch et al., 2000).
In response to this type of injury, altered muscle fibers undergo
repeated cycles of necrosis and regeneration, during which satellite
cells, the primary myogenic precursor cells of the muscle, activate
muscle regeneration process (Le Grand and Rudnicki, 2007; Biressi
and Rando, 2010). However, the regenerative process is rather inef-
ficient and the repeated cycles of necrosis and regeneration lead
to satellite cell depletion and gradual replacement of muscle by fat
and connective tissue; this process is responsible for progressive
muscle wasting and weakness. This may be attributed to a great
extent to the loss of dystrophin.
Dystrophin is essential for maintenance of muscle membrane
integrity; it is a scaffolding protein that recruits other struc-
tural and signaling proteins to the sarcolemma, forming a well-
organized multimeric dystrophin-associated glycoprotein com-
plex. The dystrophin-associated glycoprotein complex is com-
posed of several transmembrane and peripheral proteins, depend-
ing on the tissue, in particular it encloses different sarcoplas-
mic proteins [α- and β-dystrobrevins, α1-, β1-, β2-, γ1-, and
γ2-syntrophins, and neuronal nitric oxide synthase (nNOS)],
transmembrane proteins (β-dystroglycan, α-, β-, γ-, δ-, ε-, and
ζ-sarcoglycans, sarcospan, and caveolin-3), and extracellular pro-
teins (α-dystroglycan and laminin). Dystrophin-associated glyco-
protein complex plays a key role in the mechanical stabilization of
the sarcolemma during muscle contractions (Straub and Camp-
bell, 1997), and acts as a scaffold for different proteins implicated in
intracellular signaling. The proteins inside dystrophin-associated
glycoprotein complex are tightly connected to each other and
abnormalities affecting one of these proteins lead to changes in the
others impairing muscle function. Of importance, the disruption
of the dystrophin-associated glycoprotein complex in DMD also
causes the delocalization of the nNOS from sarcolemma, leading
to a reduced generation of NO. NO is important in skeletal mus-
cle physiology as it controls excitation–contraction coupling and
energy balance (De Palma and Clementi, 2012). The loss of NO-
dependent signaling pathways contributes significantly to impair
muscle bulk and force generation with increased fatigability (De
Palma and Clementi, 2012). Moreover, the loss of sarcolemmal
nNOS contributes to increase the muscle fibers susceptibility to
ischemia during exercise, and to mechanical damage resulting in
a focal muscle injury, dependent on muscle use (Thomas, 2013).
MOUSE MODELS
In DMD, different mouse models with mutations in dystrophin
gene have been generated. The mdx mouse on C57BL/10ScSn
genetic background (C57BL/10ScSn-Dmdmdx, here referred as
“mdx mouse”) (Coulton et al., 1988) shows a point mutation in
exon 23, generating an early stop codon and leading to the absence
of full-length dystrophin (Willmann et al., 2009). Other mod-
els bearing different mutations have been also generated, as for
instance mdx2cv, mdx3cv, mdx4cv, or mdx5cv mouse (Im et al.,
1996), mdx52 (with mutation on exon 52; Araki et al., 1997), and
mdx/utr−/− (mdx mouse with additional knockout of utrophin)
(Deconinck et al., 1997).
Among these models, the mdx mouse is the most commonly
used (Nakamura and Takeda, 2011). The mutation on exon 23
is wide spread and affects one-third of DMD patients (Willmann
et al., 2009).mdx mice have a shorter life compared to controls and
display a decreased relative muscle force, whereas absolute muscle
force is unaffected. Isolated muscles show a reduced force contrac-
tion, even if lacking standard condition of analysis is difficult to
compare results from different groups.
Degeneration, regeneration, and necrosis are processes
observed in young mdx mice (2–4 weeks) that result in increased
number of regenerating-centronucleated fibers and in the het-
erogeneity of myofibers area (McGeachie et al., 1993). Necrotic
fibers can be found at any age with very high frequency after
18 months (Nakamura and Takeda, 2011). Muscles undergo fre-
quent cycles of necrosis/regeneration, associated with weakness
and muscle loss. These cycles of regeneration lead to a muscle
phenotype milder than the one observed in human patients. Fibro-
sis appears to be much less than in DMD patients, except for
diaphragm muscle (Nakamura and Takeda, 2011). Although the
mdx mouse diaphragm reproduces the degenerative changes of
DMD, respiratory complications are visible only in 16-month-old
mice (Stedman et al., 1991; Nakamura and Takeda, 2011). Muscle
pathology can be worsened by forced exercise; this is a viable strat-
egy to worsen the disease phenotype and better reveal the efficacy
of new therapies.
Of importance,mdx mouse also displays cardiomyopathy, char-
acterized by fibrosis and presence of necrosis and inflammation,
thus sharing some aspects of DMD-patients cardiomyopathy and
constitute a good model to investigate cardio-protective candidate
molecules (Quinlan et al., 2004).
AUTOPHAGY AND ITS ROLE IN SKELETAL MUSCLE
HOMEOSTASIS
Autophagy is a crucial mechanism involved in the turnover
of cell components both in constitutive and catabolic (stress,
nutrient deprivation, cytokines, amino acids deprivation) condi-
tions. Autophagy classically functions as a physiological process
to degrade cytoplasmic components, protein aggregates, and/or
organelles, and as a regulator of cellular architecture. Autophagy
in mammals generally protects the cells from death and defective
autophagy can be associated with several diseases including can-
cer, neurodegenerative diseases, infectious diseases, and metabolic
diseases (Cervia et al., 2013; Jiang and Mizushima, 2014; Schneider
and Cuervo, 2014).
So far, three different mechanisms of autophagy have been
described: macroautophagy, microautophagy, and chaperone-
mediated autophagy. The most part of the information on
autophagy in skeletal muscle is about macroautophagy, a process
characterized by membranes that grow in size to generate dou-
ble membrane-structures termed autophagosome, that enclose
organelles, portion of cytoplasm, or protein aggregates. In this
process, small ubiquitin-like proteins are required for the for-
mation of autophagosomes and they are covalently bound to
phosphatidylethanolamine.
Autophagy was considered initially as a non-specific degrada-
tion mechanism, but over the years selective forms of autophagy
have been identified. For instance, selective removal of organelles,
such as mitochondria or peroxisomes occurs via specific types of
autophagy, termed mitophagy or peroxophagy, respectively.
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AUTOPHAGIC SIGNALING
The molecular signaling pathway leading to autophagy is
very complex and regulated by autophagy-related genes (Atgs),
which are connected with the formation of autophago-
somes (Hurley and Schulman, 2014). The protein products
of Atgs are organized in five functional groups, namely:
(i) the Unc-51-like kinase (Ulk):Atg13:FIP200 initiation com-
plex (Ganley et al., 2009; Hosokawa et al., 2009); (ii)
the beclin1:hVps34[phosphatidylinositol 3 (PI3) kinase]:Atg14L
nucleation complex (Itakura et al., 2008); (iii) the PI3–phosphate-
binding WIPI-1/2 complex (Proikas-Cezanne et al., 2004; Vergne
et al., 2009); (iv) the Atg5–Atg12 conjugation complex activated by
Atg7 (Mizushima et al., 1998); and (v) the Atg8 (LC3) conjugation
system (Kabeya et al., 2000). These protein complexes participate
at specific stages in the autophagic process: initiation, formation,
elongation, and fusion (Mehrpour et al., 2010; Awan and Deng,
2014); they are also controlled by several other signaling pathways
that fine tune autophagy to regulate the pace of autophagosome
formation.
A key player in the control of autophagy is the mammalian tar-
get of rapamycin (mTOR), which together with raptor (regulatory
associated protein of mTOR), G protein β-subunit-like protein
(GβL) and proline-rich Akt substrate of 40 kDa (PRAS40) forms
the multiprotein complex, mTORC1. The activity of mTOR, a
negative regulator of autophagy, depends on several positive sig-
nals including normoxia, amino acid supply, high energy levels,
or growth factors. Upon stimulation by growth factors or nutri-
ents (glucose, amino acids), mTORC1 negatively regulates the
macromolecular initiation complex Ulk:Atg13:FIP200 leading to
autophagy suppression (Ganley et al., 2009; Hosokawa et al., 2009;
Wong et al., 2013). Conversely, starvation and energy depletion,
which stimulate autophagy, inhibit mTORC1, leading to the acti-
vation of Ulk (Jung et al., 2010; Kim et al., 2011; Mihaylova and
Shaw, 2011).
The main signaling pathway controlling mTORC1 is the PI3
kinase/Akt pathway activated by the binding of growth factors or
insulin to their cell surface receptors. Activated Akt in turn phos-
phorylates and inhibits the tuberous sclerosis complex 2 (TSC2),
thus preventing the formation of the inhibitory TSC1/TSC2 het-
erodimer. This inhibition allows the small GTPase Rheb to activate
directly mTORC1 (Long et al., 2005a,b; Huang and Manning,
2009) and to inhibit autophagy. Another signaling pathway con-
trolling mTOR is the adenosine monophosphate-activated protein
kinase (AMPK) pathway activated under energy-low conditions
(Alers et al., 2012). Activated AMPK is known to regulate mTORC1
activity mainly through the phosphorylation and consequent acti-
vation of the negative regulator TSC2 (Inoki et al., 2003). However,
the discovery that TSC2-deficient cells can respond to a decrease
in energy levels has led to the investigation of additional mecha-
nisms. Recently, it has been demonstrated that both mTORC1 and
AMPK can act on the same substrate, Ulk1, with opposite effects:
mTORC1 inhibits Ulk1 activation by phosphorylating Ser757;
conversely, AMPK activates Ulk1 through its phosphorylation on
Ser317 and Ser777 (Kim et al., 2011).
Additional proteins have been found to be associated with
mTOR, i.e., rictor (rapamycin-insensitive companion of mTOR),
GβL, SAPK-interacting protein 1 (SIN1), and protein observed
with rictor (PROTOR), to form the multiprotein complex
mTORC2 (Sarbassov et al., 2006). mTORC2 is involved in the
phosphorylation and activation of Akt, thereby promoting its
prosurvival action. Through this activation, mTOR determines
the downregulation of the transcription factor Forkhead Box O3
(FoxO3), particularly important in muscle where it stimulates
autophagy by enhancing the expression of genes including Atg12,
Ulk1, Atg4b, and Gabarapl1 (Mammucari et al., 2007).
AUTOPHAGY LEVELS AND SKELETAL MUSCLE IMPAIRMENT
The role of autophagy in skeletal muscle has been investigated
extensively (Sandri, 2010; Neel et al., 2013). Muscle mass repre-
sents 40–50% of the human body and is one of the most important
sites for the regulation of metabolism. Excessive protein degrada-
tion in the skeletal muscle is detrimental for the economy of the
body and can lead to death. Studies in mice with muscle-specific
inactivation of autophagic genes have been used to identify the
role of autophagy in muscles (Sandri, 2010; Neel et al., 2013).
Briefly, ablation of Atg7 gene led to an altered muscle struc-
ture, with sarcomere disorganization and myofibers degeneration
due to activation of an unfolded protein response, accumula-
tion of abnormal mitochondria, enhanced oxidative stress, and
increased concentration of polyubiquitinated proteins (Masiero
et al., 2009). Altogether, these effects accounted for muscle weak-
ness, atrophy, and other signs of myopathy such as an irregular
distribution of fibers’ shape as well as fibers with a vacuolated
cytosol. In general, the blocking of basal autophagy in muscle
enhanced the accumulation of damaged and dysfunctional mito-
chondria, suggesting that mitophagy was impaired and critical
to maintain muscle homeostasis (Masiero et al., 2009). Further,
muscle-specific Atg5−/− mice displayed an atrophic phenotype
in the fibers of the fast type, associated to accumulation of
autophagic substrates, for instance, ubiquitinated proteins (Raben
et al., 2008). In particular, in fast muscles of Atg5−/− mice, the
size and density of lysosomes were increased and their distribu-
tion on the microtubules altered. Microtubules displayed a more
linear organization compared to that of wild-type mice, demon-
strating that autophagy is crucial also for the correct arrangement
of microtubules (Raben et al., 2008).
Finally, in studies in which the transcription of FoxO3
was upregulated an enhanced autophagy–lysosome system was
observed, especially during muscle wasting and the factor itself
was enough to enhance autophagy process and to trigger atro-
phy (Mammucari et al., 2007). Noteworthy, a recent study
showed that mice lacking the nutrient-deprivation autophagy
factor-1, displayed muscle weakness, associated with an increased
autophagy, dysregulation of calcium and accumulation of enlarged
mitochondria (Chang et al., 2012).
The lesson from these results is complex and indicates a dual
role for autophagy in skeletal muscle homeostasis: at high lev-
els, it can be detrimental and contribute to muscle atrophy; at
low levels, it can cause weakness and muscle degeneration, due to
the unchecked accumulation of damaged proteins and organelles
(Sandri, 2010; Sandri et al., 2013). Thus, a proper autophagic
process is vital for both functional skeletal muscle, which con-
trols the support and movement of the skeleton, and muscle
metabolism (Neel et al., 2013).
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DEREGULATION OF AUTOPHAGY IN DUCHENNE MUSCULAR
DYSTROPHY
The fact that manipulation of animal models to dysregulate
autophagy also leads to muscle pathology has prompted studies
to investigate whether this process is altered in muscle diseases
(Neel et al., 2013; Sandri et al., 2013). Of interest, our under-
standing on the role of detective autophagy in different forms of
inherited muscular dystrophies, including Bethlem myopathy, Ull-
rich congenital muscular dystrophy, merosin-deficient congenital
muscular dystrophy, and Emery–Dreifuss muscular dystrophy has
emerged in the past 5 years (Sandri et al., 2013).
As initially postulated from indirect evidence, deficient
autophagy was suggested to contribute to DMD pathogenesis.
The presence of swollen and damaged mitochondria, protein
aggregation, and distension of sarcoplasmic reticulum, which are
cyto-pathological hallmarks of DMD, are often observed when
autophagy is impaired (Culligan et al., 2002; Zhao et al., 2007). In
addition, activation of Akt was significantly higher in muscles from
mdx mice and dystrophin-deficient primary myotubes, thereby
suggesting a defective autophagic process (Dogra et al., 2006; Peter
and Crosbie, 2006). In line with these observations, DMD patients
were found to exhibit a similar pattern of Akt activation (Peter and
Crosbie, 2006).
The causal relationship between DMD pathogenesis and dys-
functional autophagy has been investigated more recently in
studies addressing this issue specifically. A severe impairment of
autophagy was indeed demonstrated by biochemical and ultra-
structural analyses in muscles from patients affected by DMD
and mdx mice. In particular, these muscles display a significant
reduction in the lipidated form of the protein LC3, which is a com-
mon marker of autophagy induction (De Palma et al., 2012; Bibee
et al., 2014). The reduction in lipidated LC3 has been found to be
accompanied by clear signs of impaired autophagy at the ultra-
structural level, i.e., by the presence of damaged organelles, the
increase in the signaling adaptor p62 protein (a marker inversely
correlated with autophagic flux), and the decrease of Bnip3, a
mitochondrial protein, which recruits LC3 to mitochondria (De
Palma et al., 2012; Bibee et al., 2014). Recent studies have also
shown a role for the TNF receptor-associated factor 6 (TRAF6) as
an important regulator of autophagy. In skeletal muscle of mdx
mice, the activity of TRAF6 is increased and its absence corre-
lates with a reduced autophagy (Hindi et al., 2014). Strikingly, this
study also reported that the inhibition of TRAF6 signaling deterio-
rates muscle pathology at later stages of disease progression. It has
been thus hypothesized that the initial inhibition of autophagy in
youngmdx mice in the absence of TRAF6 gene may be a protective
mechanism to preserve skeletal muscle mass. Autophagy emerges
then as an essential process for the clearance of defunct cellular
organelles and a continued inhibition of autophagy exaggerates
dystrophic phenotype (Hindi et al., 2014). The beneficial effects
of activating autophagy in mdx mice have been also confirmed
by overexpressing peroxisome proliferator-activated receptor γ
coactivator 1α (PGC-1a), a transcriptional coactivator, which is
a powerful mediator of muscle plasticity (Hollinger et al., 2013)
and by pharmacological treatment with an agonist drug against
the energy sensor AMPK, i.e., 5-aminoimidazole-4-carboxamide-
1-β-d-ribofuranoside (AICAR) (Pauly et al., 2012). In particular,
AICAR treatment led to a significant activation of the autophagy,
as indicated by the characteristic biochemical changes of increased
lipidated LC3 content, an upregulation of other prototypical
autophagy-associated proteins, and to significant improvements
in both muscle structure and maximum force-generating capacity
(Pauly et al., 2012).
From a functional point of view, it has been recently shown that
voluntary exercise in mdx mice enhances markers of autophagy to
or above the levels observed in healthy mice, thus suggesting that
beneficial autophagy can be induced by exercise (Hulmi et al.,
2013). In agreement with these data, fasting induced autophagy in
wild-type and mdx mice diaphragm (Spitali et al., 2013). Interest-
ingly in mdx mice, the ability of upregulating autophagy appears
restricted to certain muscles: tibialis anterior muscle of mdx mice
are unable to enhance autophagy in response to fasting, which
induces autophagy in tibialis anterior muscle of wild-type mice.
MOLECULAR CHARACTERISTICS
The defect in autophagy of mdx mouse muscles is accompanied
by persistent activation of the Akt–mTOR axis (Figure 1) and
its related autophagy-inhibiting pathways, and the concomitant
downregulation of several autophagy-inducing genes (Dogra et al.,
2006; Peter and Crosbie, 2006; De Palma et al., 2012). In particular,
Akt activation has been established to occur at very early, pre-
necrotic stages of disease pathogenesis, with a progressive increase
with disease worsening (Peter and Crosbie, 2006). This high acti-
vation of Akt stimulates in turn the mTOR-dependent pathways
whereas the mTOR-independent axis is not significantly altered
(Dogra et al., 2006; Peter and Crosbie, 2006). The involvement
of the mTOR axis in the pathogenesis of mdx mice is demon-
strated also by the effects of the mTOR-targeting, immunosup-
pressant drug rapamycin. Oral or injected rapamycin treatment
has been shown to improve histopathological features of dystrophy
(Eghtesad et al., 2011) and the treatment with rapamycin-loaded
nanoparticles (RNPs) has been shown to increase skeletal mus-
cle strength in both young and adult mice concomitantly to an
increased mTOR-dependent autophagy (Bibee et al., 2014). Con-
sistently, mdx mice treatment with a long-term low-protein diet
reactivates autophagy in muscle fibers, with increased lipidation
of LC3, reduced levels of p62, normalization of Akt and mTOR
signaling, a reduced accumulation of damaged organelles, and a
significant recovery of muscle inflammation, fibrosis, myofiber
damage and muscle function (De Palma et al., 2012). Since the
long-term low-protein diet was shown to preserve the regener-
ating ability of mdx mouse muscle, it is tempting to speculate
that physiological levels of autophagy maintain the number and
function of myogenic precursor cells.
The picture is not completely clear and some controversies still
exist and issues remain to be solved. Spitali et al. (2013) reported
that autophagy levels and Akt axis activation in mdx mice is sim-
ilar to wild-type control mice. Likewise, a study on Akt–mTOR
axis activation in very old mdx mice correlated the advancing
of age with a reduction in mTOR signaling in dystrophic mus-
cles (Mouisel et al., 2010). In another study, however, it was also
reported that mTOR activation is increased by age in diaphragm
muscle of wild-type mice, but not in mdx mice, while similar lev-
els of mTOR activation were found in tibialis anterior muscles
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FIGURE 1 | Schematic illustration of the correlation between autophagy
and Duchenne muscular dystrophy. Basal autophagy levels are required for
muscle homeostasis and for the maintenance of healthy myofibers. In DMD,
muscle autophagy is impaired contributing to muscle degeneration. This
autophagy inhibition is dependent on the iper-activation of Akt–mTOR axis.
Treatments with rapamycin or low-protein diet, acting on Akt pathway, restore
autophagy ameliorating DMD muscle phenotype and function. The impaired
autophagy may also occur independently of Akt. Treatments with AMPK
agonists, which increase AMPK activation, counteract the Akt-independent
axes enhancing autophagy and inducing a positive effect in DMD muscle.
(Eghtesad et al., 2011). Although these data are apparently diffi-
cult to reconcile, different confounding factors may explain them,
as for instance the fact that mdx mice undergo extensive muscle
regeneration between 6 and 12 weeks. Furthermore, the fact that
the regulation of autophagy in mdx mice was indicated to differ
depending on the muscle type (Spitali et al., 2013) should be taken
into consideration, with the glycolytic muscles showing a process
of vesicles formation significantly greater than oxidative muscles
(Mizushima et al., 2004).
Autophagy can be modulated inmdx mice also through mTOR-
independent mechanisms (Figure 1). Chronic AICAR adminis-
tration induced autophagy in mdx muscles, with a significant
upregulation of Ulk1 and an increased expression of Bnip3 in
the absence of mTOR inhibition (Pauly et al., 2012). In addition, it
has been suggested that TRAF6 regulation of Akt signaling is inde-
pendent of TRAF6 regulation of autophagy (Hindi et al., 2014).
The evidence for potentially augmented autophagic signaling may
thus be suggestive of an adaptive response to attempt to rid dys-
trophic myofibers of defective and/or detrimental constituents,
such as dysfunctional mitochondria (Ljubicic and Jasmin, 2013).
The complex and apparently contrasting evidence on the role of
authophagy in mdx mice suggests that the autophagic machinery
in these mice is more complex than in wild-type mice and that a
systematic analysis taking into account the variable of time has to
be undertaken to clarify each single aspect in distinct muscles and
during disease progression.
THERAPEUTIC IMPLICATIONS OF CORRECTIVE AUTOPHAGY
IN DUCHENNE MUSCULAR DYSTROPHY
At present, there is no satisfactory therapy for DMD. The treat-
ment with corticosteroids is the actual gold standard. Treatment
with glucocorticoids significantly delays the impairment of mus-
cle force and function, extends ambulation period, and retards the
onset of pulmonary failure, cardiomyopathy, and scoliosis (Bushby
et al., 2010). These effects, however, are often only temporary and
associated with severe side effects. More than 25% of patients are
not treated with glucocorticoids due to adverse effects, such as
obesity, immune suppression, bone demineralization, associated
with negative behavioral changes, or lack of response (Bushby
et al., 2010). This strongly indicates an urgent requirement of new
clinical intervention for DMD patients.
The genetic approaches [exon skipping, viral vector-mediated
gene delivery, and cell therapy (Pichavant et al., 2011; Mendell
et al., 2012)], currently being investigated, show some degree of
success and some of them have been recently granted orphan status
by either the European Medicines Agency or the Food and Drug
Administration (http://orphandruganaut.wordpress.com/2013/
12/14/duchenne-muscular-dystrophy-2013-fda-orphan-drug-de
signations-2/). They, however, are directed to specific subsets of
population and cannot restore fully the damage already caused
by the disease to the muscle. Alternative strategies are therefore
needed and to this end identification of suitable therapeutic targets
is necessary.
In this context, pharmacological modulation of autophagy can
be considered a possible strategy aimed at delaying muscle degen-
eration (Figure 1). As mentioned above, the AICAR activating
AMPK, ameliorated phenotypic and functional features of dys-
trophic muscle (Pauly et al., 2012). AMPK pharmacological ago-
nists exist; they are clinically approved and AICAR has been tested
for ischemic damage in the heart and used in clinical trial for meta-
bolic disorders (Ljubicic and Jasmin, 2013). The beneficial effects
of AICAR in dystrophic muscle could be due to a well-known
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effect in stimulating the slow, oxidative phenotype (Ljubicic et al.,
2011). It could also be due to induction of autophagic pathways,
since AICAR stimulates the removal of damaged mitochondria via
mitophagy (Pauly et al., 2012).
A second pharmacological approach that targets autophagy
has been proposed by Bibee et al. (2014) in which RNPs were
used to successfully enhance grip strength and the left-ventricular
ejection fraction in mdx mice, ameliorating both physical and car-
diac performances. These effects with RNPs have been achieved
after administration of only eight doses of RNPs, with the final
dose within the range of recommended oral doses for immune-
suppressive therapy in patients. Interestingly, oral administration
of rapamycin at pharmacological doses was of no efficacy on
muscle strength. It appears that the way RNPs worked was via
autophagy induction, dependent on nanoparticles delivery of the
drug: rapamycin was locally delivered at high concentration thus
becoming able to trigger autophagy (Bibee et al., 2014). Inter-
estingly, at least in the mdx mice also corticosteroids induce
autophagy and this may contribute to explain their beneficial
effects.
Autophagy cannot certainly be envisaged as a stand-alone
therapeutic option. Low-protein diet regimen has been recently
hypothesized to be safely usable in the treatment of DMD patients
in combination with pharmacological treatment and cell and gene
therapies (De Palma et al., 2012). RPNs and low-protein diet might
also be used in combination with corticosteroids to act as steroids
sparing drugs, reducing their toxic effects. Low-protein diet has
been demonstrated safe and useful also in Col6a1-deficient mouse,
considered an animal model of Bethlem myopathy (Grumati et al.,
2010). Of interest, a very recent clinical study showed a clear induc-
tion of autophagy with a low-protein diet regimen in muscles from
Becker and Ulrich patients (Merlini and Nishino, 2014), further
suggesting that also in humans a strategy of autophagy reactivation
is applicable.
CONCLUSION
Autophagy has emerged as a key process whose dysregulation con-
tributes to the pathogenesis of several muscular dystrophies. The
relevance of this process is that its normalization by pharma-
cological approaches leads to an amelioration of the dystrophic
phenotype. While drugs targeting autophagy have good perspec-
tive in terms of therapy, we still need to refine them, by identifying
appropriate targets in the autophagic pathway against which to
design selected modulating drugs.
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